DALLAS, July 23, 2014 /PRNewswire/ --
Expiring biologic human insulin market drugs' patents are set to create new opportunities for biosimilar drugs, which is estimated to grow at a CAGR of 35% from 2014-2019. This, as per the report titled "Human Insulin Market by Product Type (Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed), by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2018", which is of 250 pages, published in June 2014 and available at http://www.reportsnreports.com/reports/291200-human-insulin-market-by-product-type-human-insulin-short-acting-intermediate-acting-premixed-modern-human-insulin-rapid-acting-long-acting-premixed-by-brand-lantus-apidra-levemir-novorapid-novomix-tresiba-others-forecast-to-2018.html .
Asia-Pacific will be the fastest growing market for human insulin production, development, and distribution. Further, Asia-Pacific countries are considered to be the lucrative ones for investors to invest in for manufacturing and clinical activities of pipeline and existing human insulin product. Major players enter the Asian market with the purpose to collaborate with various CMO and CRO existing in this region that fosters the development of human insulin at lower cost compared to the other region across the globe. The demand for human insulin will be on the rise in coming five years due to the high prevalence rate of diabetes as well as low price of human insulin. Countries such as China, India, Japan, and Korea will also offer potential growth opportunities to human insulin market. Of all the countries, China is estimated to be the fastest growing market for human insulin market. Saudi Arabia, Qatar, Egypt, U.A.E, and Brazil will also emerge as lucrative markets for human insulin market.
Modern human insulin accounted for the largest share -84%- of global human insulin market. Premixed modern human insulin and long acting human insulin are estimated to grow at a brisk pace over the next five years. The high growth in these segments can be attributed to the growing demand of Apidra, Lantus, and Levemir. Furthermore, these drugs reported high efficiency and effectiveness as compared to other synthetic insulin, animal insulin, and other human insulin.
New technologies such as safety pen needles and infusion pumps have emerged as efficient mode of delivery for human insulin. Pen needles offer significant benefits to the healthcare sector. The usage of easy to fit needles is rising due to the convenience offered by them. These needles are easy to attach, remove, and dispose, thus they can be easily used by patients with manual dexterity problems, and visual impairment. Diabetes educators and clinicians across the world recommend the usage of needles with shorter lengths and higher gauge sizes for convenience and to minimize pain. Owing to these factors, technological advancement is expected to be a major revenue pocket for the human insulin market in the coming years.
Companies profiled in this human insulin industry research report include Novo Nordisk, EliLilly, Sanofi Aventis, Biocon and Julphar Pharmaceuticals. Brands like Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba and Others are also discussed in this report, available for purchase at http://www.reportsnreports.com/Purchase.aspx?name=291200 .
Another study titled "Market Research Report on Global and Chinese Recombinant Human Insulin Industry, 2009-2019" starts with a review on the basic information of Recombinant Human Insulin including its classification, application and manufacturing technology; The report then explores global and China's top manufacturers of Recombinant Human Insulin listing their product specification, capacity, Production value, and market share etc.; The report further analyzes quantitatively 2009-2014 global and China's total market of Recombinant Human Insulin by calculation of main economic parameters of each company; The breakdown data of Recombinant Human Insulin market are presented by company, by country, and by application; The report also estimates 2014-2019 market development of Recombinant Human Insulin Industry. The report then analyzes the upstream raw materials, downstream clients, and current market dynamics of Recombinant Human Insulin Industry. In the end, the report makes some proposals for a new project of Recombinant Human Insulin Industry and a new project of Recombinant Human Insulin Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2009-2014 global and China Recombinant Human Insulin industry covering all important parameters. Spread across 150 pages and published in Feb 2014, this report provides company profiles of 10 market players and is available at http://www.reportsnreports.com/reports/277255-market-research-report-on-global-and-chinese-recombinant-human-insulin-industry-2009-2019.html .
Explore more reports on insulin market and overall pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
List of Figures provided in Human Insulin Market by Product Type (Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed), by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2018 research report include:
Figure 1 Research Methodology
Figure 2 Market Size Estimation Methodology
Figure 3 Data Triangulation Methodology
Figure 4 Biologic Vs. Biosimilar Human Insulin: Market Size forecast, 2011-2018
Figure 5 Human Insulin Market, Traditional Vs. Modern Human Insulin,2014-2019 ($Million)
Figure 6 Human Insulin Market, Biologics Vs. Biosimilar,2014-2019 ($Million)
Figure 7 Human Insulin Market, By Brands,2014-2019 ($Million
Figure 8 Human Insulin Market,Sub Segment of Biopharmaceutical Market
Figure 9 Human Insulin Market Snapshot,2013($Million)
Figure 10 Human Analysis Market,Geographic Analysis,By Product,2013($Million)
Figure 11 Market Dynamics : Human Insulin Market
Figure 12 Opportunity Matrix: Global Human Insulin Market, By Brands,2013
Figure 13 Human Insulin Timeline
Figure 14 Human Insulin,Market Segmentation
Figure 15 Market Share Analysis, By Key Players
Figure 16 Prther's Five force Analysis
Figure 17 Major Potential Market
Figure 18 Modern Human Insulin Market, By Types, 2014 Vs 2019 ($Million
Figure 19 Traditional Human Insulin Market, By Brand, 2014 Vs2019 ($Million
Figure 20 Modern Human Insulin Market, By Brand, 2014 Vs 2019 ($Million
Figure 21 Opportunity Matrix; Human Insulin Market , By Geography ,2014
Figure 22 Opportunity Matrix : Human Insulin Market, By Country ,2014
Figure 23 Key Growth Strategies, 2011-2014
Figure 24 Novo Nordisk: Geographic Presence (Manufacturing Unit)
Figure 25 Novo Nordisk: Financials, 2011-2013($Million)
Figure 26 Novo Nordisk: Buisness Revenue Mix,2013,($Million)
Figure 27 Novo Nordisk: Geographic Revenue Mix,2013,($Million)
Figure 28 Eli Lilly: Geographic Presence (Manufacturing Unit)
Figure 29 Eli Lilly: Financials, 2011-2013($Million)
Figure 30 Eli Lilly: Buisness Revenue Mix,2013,($Million)
Figure 31 Eli Lilly: Geographic Revenue Mix,2013,($Million)
Figure 32 Sanofi Aventis : Geographic Presence (Manufacturing Unit)
Figure 33 Sanofi Aventis: Financials, 2011-2013($Million)
Figure 34 Sanofi Aventis: Buisness Revenue Mix,2013,($Million)
Figure 35 Sanofi Aventis: Geographic Revenue Mix,2013,($Million)
Figure 36 Biocon : Geographic Presence (Manufacturing Unit)
Figure 37 Biocon: Financials, 2011-2013($Million)
Figure 38 Biocon: Buisness Revenue Mix,2013,($Million)
Figure 39 Biocon: Geographic Revenue Mix,2013,($Million)
Figure 40 Julphar Pharmaceuticals : Geographic Presence (Manufacturing Unit)
Figure 41 Julphar Pharmaceuticals: Financials, 2011-2013($Million)
Figure 42 Julphar Pharmaceuticals: Buisness Revenue Mix,2013,($Million)
Figure 43 Julphar Pharmaceuticals: Geographic Revenue Mix,2013,($Million)
ReportsnReports.com is an online market research reports library of 450,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.
Connect With Us on: